Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients
{{custom_author.name}}, {{article.zuoZheEn}}
Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients
[{{custom_ref.label}}] |
{{custom_citation.content}}
|
/
〈 | 〉 |